A5053328129- PARP inhibition in cancer therapy
- DNA Repair Mechanisms
- Estrogen and related hormone effects
- Advanced Breast Cancer Therapies
- Genomics and Phylogenetic Studies
- Breast Cancer Treatment Studies
- Bacteriophages and microbial interactions
- BRCA gene mutations in cancer
- CRISPR and Genetic Engineering
- Evolution and Genetic Dynamics
- RNA and protein synthesis mechanisms
- Bacterial Genetics and Biotechnology
- Protist diversity and phylogeny
- Genetic diversity and population structure
- Drug Transport and Resistance Mechanisms
- Microbial Community Ecology and Physiology
- Metal complexes synthesis and properties
- Pediatric Hepatobiliary Diseases and Treatments
- Chromosomal and Genetic Variations
- Viral gastroenteritis research and epidemiology
- Liver Disease Diagnosis and Treatment
- Gallbladder and Bile Duct Disorders
- Cancer Cells and Metastasis
- Animal Genetics and Reproduction
- Evolution and Paleontology Studies
Dartmouth College
2017-2025
Dartmouth Cancer Center
2023-2024
Monmouth College
2024
University of Connecticut
2012-2018
Several bacterial and archaeal lineages produce nanostructures that morphologically resemble small tailed viruses, but, unlike most contain apparently random pieces of the host genome. Since these elements can deliver packaged DNA to other cells, they were dubbed gene transfer agents (GTAs). Because many genes involved in GTA production have viral homologs, it has been hypothesized ancestor was a virus. Whether GTAs represent an atypical virus, defective or virus co-opted by prokaryotes for...
Abstract Despite adjuvant treatment with endocrine therapies, estrogen receptor-positive (ER+) breast cancers recur in a significant proportion of patients. Recurrences are attributable to clinically undetectable endocrine-tolerant persister cancer cells that retain tumor-forming potential. Therefore, strategies targeting such may prevent recurrent disease. Using CRISPR-Cas9 genome-wide knockout screening ER+ cells, we identified survival mechanism involving metabolic reprogramming reliance...
<p>Suppl. Figure 6</p>
<p>Suppl. Figure 1</p>
<p>Suppl. Figure 4</p>
<p>Suppl. Figure 2</p>
<p>Suppl. Figure 5</p>
<p>Clinical study protocol (version 11October2021)</p>
<p>Suppl. Figure 8</p>
<p>L:egends for Suppl. Figs. 1-8</p>
<p>Suppl. Figure 3</p>
<div>Abstract<p>Despite adjuvant treatment with endocrine therapies, estrogen receptor–positive (ER<sup>+</sup>) breast cancers recur in a significant proportion of patients. Recurrences are attributable to clinically undetectable endocrine-tolerant persister cancer cells that retain tumor-forming potential. Therefore, strategies targeting such may prevent recurrent disease. Using CRISPR-Cas9 genome-wide knockout screening ER<sup>+</sup> cells, we...